Description: An Open Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-105 in Subjects with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Target Patient Population: PD-L1+ (CPS ≥ 5) Melanoma, NSCLC, Head and Neck Squamous cell
Study Design: Drug is given IV every 3 weeks